C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences

Current HIV Research

Volumn 3, Issue 2, 2005, Pages 191-198

  Bower, Joseph F ^a   Sanders, Kelly L ^a,b   Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

C3d; Codon optimization; DNA vaccine; Gene gun; Molecular adjuvant

Indexed keywords

COMPLEMENT COMPONENT C3D; DNA VACCINE; DRUG VEHICLE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; PLASMID DNA; PROTEIN ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; CODON; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENVELOPE GENE; EXPRESSION VECTOR; GENE GUN; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; REVIEW; VIRUS ENVELOPE; VIRUS GENE; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; BIOLISTICS; CODON; COMPLEMENT C3D; CYTOKINES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; MICE; MICE, INBRED BALB C; SPLEEN; VACCINATION; VACCINES, CONJUGATE; VACCINES, DNA;

EID: 18144428368     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570162053506937     Document Type: Review

References (41)

1. Amara, RR and Robinson, HL (2002). A new generation of HIV vaccines. Trends in Molecular Medicine 8: 489-495.
2. Andre, S, Seed, B, Eberle, J, Schraut, W, Bultmann, A and Haas, J (1998). Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. Journal of Virology 72: 1497-1503.
3. Bojak, A, Wild, J, Demi, L and Wagner, R (2002). Impact of codon usage modification on T cell immunogenicity and longevity of HIV-1 gag-specific DNA vaccines. Intervirology 45: 275-286.
4. Bower, JF, Green TD, Ross TM (2004). DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology 328: 292-300.
5. Bower, JF, Yang, X, Sodroski, J and Ross, TM (2004). Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. Journal of Virology 78: 4710-4719.
6. Burton, DR, Desrosiers, RC, Doms, RW, Koff, WC, Kwong, PD, Moore, JP, Nabel, GJ, Sodroski, J, Wilson, IA and Wyatt, RT (2004). HIV vaccine design and the neutralizing antibody problem. Nature Immunology 5: 233-236.
7. Cole, KS, Rowles, JL, Jagerski, BA, Murphey-Corb, M, Unangst, T, Clements, JE, Robinson, J, Wyand, MS, Desrosiers, RC and Montelaro, RC (1997). Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. Journal of Virology 71: 5069-5079.
8. Corbet, S, Vinner, L, Hougaard, DM, Bryder, K, Nielsen, HV, Nielsen, C and Fomsgaard, A (2000). Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Research and Human Retroviruses 16: 1997-2008.
9. Dai, G, Steede, NK and Landry, SJ (2001). Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120. Journal of Biological Chemistry 276: 41913-41920.
10. Deml, L, Bojak, A, Steck, S, Graf, M, Wild, J, Schirmbeck, R, Wolf, H and Wagner, R (2001). Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. Journal of Virology 75: 10991-11001.
11. Deml, L, Schirmbeck, R, Reimann, J, Wolf, H and Wagner, R (1999). Immunostimulatory CpG motifs trigger a T helper-I immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clinical Chemistry and Laboratory Medicine 37: 199-204.
12. Dempsey, PW, Allison, ME, Akkaraju, S, Goodnow, CC and Fearon, DT (1996). C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
13. Donnelly, JJ, Ulmer, JB and Liu, MA (1998). DNA vaccines. Developments in Biological Standardization 95: 43-53.
14. Gao, F, Li, Y, Decker, JM, Peyerl, FW, Bibollet-Ruche, F, Rodenburg, CM, Chen, Y, Shaw, DR, Allen, S, Musonda, R, Shaw, GM, Zajac, AJ, Letvin, N and Hahn, BH (2003). Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice. AIDS Research and Humun Retroviruses 19: 817-823.
15. Graham, BS and Wright, PF (1995). Candidate AIDS vaccines. New England Journal of Medicine 333: 1331-1339.
16. Green, TD, Monteftori, DC and Ross, TM (2003). Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. Journal of Virology 77: 2046-2055.
17. Green, TD, Newton, BR, Rota, PA, Xu, Y, Robinson, HL and Ross, TM (2001). C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20: 242-248.
18. Haas, J, Park, EC and Seed, B (1996). Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Current Biology 6: 315-324.
19. Haas, KM, Toapanta, FR, Oliver, JA, Poe, JC, Weis, JH, Karp, DR, Bower, JF, Ross, TM and Tedder, TF (2004). Cutting Edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. Journal of Immunology 172: 5833-5837.
20. Kang, CY, Luo, L, Wainberg, MA and Li, Y (1999). Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biological Chemistry 380: 353-364.
21. Liu, F, Mboudjeka, I, Shen, S, Chou, TH, Wang, S, Ross, TM and Lu, S (2004). Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gpl20 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine 22: 1764-1772.
22. Liu, MA, Fu, TM, Donnelly, JJ, Caulfield, MJ and Ulmer, JB (1998). DNA vaccines. Mechanisms for generation of immune responses. Advances in Experimental Medicine and Biology 452: 187-191.
23. Luo, L, Li, Y, Chang, JS, Cho, SY, Kim, TY, Choi, MJ, Cheong, HS, Kim, HJ, Ahn, HJ, Min, MK, Chun, BH, Jung, SM, Woo, SG, Park, SY and Kang, CY (1998). Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120. Virology 240: 316-325.
24. Mitchell, JA, Green, TD, Bright, RA and Ross, TM (2003). Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21: 902-914.
25. Mustafa, F, Richmond, JF, Fernandez-Larsson, R, Lu, S, Fredriksson, R, Fenyo, EM, O'Connell, M, Johnson, E, Weng, J, Santoro, JC and Robinson, HL (1997). HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. Virology 229; 269-278.
26. Oran, AE and Robinson, HL (2003). DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells. Journal of Immunology 171: 1999-2005.
27. Richmond, JF, Lu, S, Santoro, JC, Weng, J, Hu, SL, Montefiori, DC and Robinson, HL (1998). Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. Journal of Virology 72: 9092-9100.
28. Robinson, HL (1997). DNA vaccines for immunodeficiency viruses. AIDS 11: S 109-119.
29. Robinson, HL (2002). New hope for an AIDS vaccine. Nature Reviews in Immunology 2: 239-250.
30. Robinson, HL and Pertmer, TM (2000). DNA vaccines for viral infections: basic studies and applications. Advances in Virus Research 55: 1-74.
31. Ross, TM, Xu, Y, Bright, RA and Robinson, HL (2000). C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nature Immunology 1: 127-131.
32. Ross, TM, Xu, Y, Green, TD, Montefiori, DC and Robinson, HL (2001). Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Research and Humun Retroviruses 17: 829-835.
33. Suradhat, S, Yoo, D, Babiuk, LA, Griebel, P and Baca-Estrada, ME (1997). DNA immunization with a bovine rotavirus VP4 gene induces a Th1-like immune response in mice. Viral Immunology 10: 117-127.
34. Terrazzini, N, Hannesdottir, S, Delves, PJ and Lund, T (2004). DNA immunization with plasmids expressing hCGbeta-chimeras. Vaccine 22: 2146-2153.
35. Test, ST, Mitsuyoshi, J, Connolly, CC and Lucas, AH (2001). Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infection and Immunity 69: 3031-3040.
36. Toapanta, FR and Ross, TM (2004). Mouse strain-dependent differences in enhancement of immune responses by C3d. Vaccine 22: 1773-1781.
37. Vinner, L, Nielsen, HV, Bryder, K, Corbet, S, Nielsen, C and Fomsgaard, A (1999). Gcne gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine 17: 2166-2175.
38. Wang, L, Sunyer, JO and Bello, LJ (2004). Fusion to C3d enhances the immunogenicity of the E2 glycoprotein of type 2 bovine viral diarrhea virus. Journal of Virology 78: 1616-1622.
39. Wang, XL, Li, DJ, Yuan, MM, Yu, M and Yao, XY (2004). Enhancement of humoral immunity to the hCGbeta protein antigen by fusing a molecular adjuvant C3d3. Journal of Reproductive Immunology 63: 97-110.
40. Zolla-Pazner, S (2004). Identifying epitopes of HIV-1 that induce protective antibodies. Nature Reviews in Immunology 4: 199-210.
41. zur Megede, J, Chen, MC, Doe, B, Schaefer, M, Greer, CE, Selby, M, Otten, GR and Barnett, SW (2000). Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. Journal of Virology 74: 2628-2635.